Group 1: Giant Biogene - Giant Biogene reported 1H25 revenue of RMB3,113 million, up 22.5% YoY, representing 46% of prior full-year estimate, in line with historical seasonality [1] - Gross margin declined slightly to 81.7%, down 0.7 percentage points YoY, mainly due to a more diversified product mix [1] - Sales growth on JD accelerated significantly in 1H25, evidenced by a 134% YoY increase in direct-to-platform e-commerce sales [1] - Total revenue is expected to grow 21.4% YoY in 2H25E [1] Group 2: Comfy Brand - Comfy's revenue increased by 23% YoY to RMB2,542 million in 1H25, driven by solid performance across multiple product lines [2] - Second-tier products such as Collagen Toner and Lotion and Hydration Series outpaced the Company's overall growth [2] - Focus Cream surpassed its 2024 revenue, reaching over RMB200 million in 1H25 [2] - The flagship Collagen Stick maintained strong customer acquisition capabilities, with new customers accounting for over 60% of sales in 1H25 [2] Group 3: Collgene Brand - Collgene's revenue reached RMB503 million, up by 27% YoY, driven by strong online momentum [3] - The upgraded Collage Mask King 3.0 ranked TOP4 on Tmall's Mask Hot Sales List and TOP1 on JD.com's Nourishing Mask List during the 618 Shopping Festival [3] - Offline channel contraction continues to drag Collgene's overall growth, but a pickup in growth momentum is anticipated from 2H25E onward driven by robust online sales [3] Group 4: Influencer Live-Streaming - In August, Li Jiaqi launched the variety show The Chinese Beauty Shop, generating over 100 million cumulative exposures, significantly boosting brand visibility [4] - Top Douyin KOL Sun Jian live-streamed Collagen Mask King 3.0 in August [4] - The Company plans further collaborations with leading influencers on Tmall and Douyin, which should further boost online sales in 2H25E [4] Group 5: Investment Outlook - The BUY rating is maintained while slightly lowering the 2025E revenue growth forecast to 22%, reflecting continued offline pressure for Collgene in 2H25E [5] - The target price is revised down to HK$71.30, implying 29x 2025E P/E [5]